Multiple Versus Single Antipsychotic Agents for Hospitalized Psychiatric Patients: Case-Control Study of Risks Versus Benefits
American Journal of PsychiatryPublished 31 March 2004
Franca Centorrino, Jessica L. Gören, John Hennen, Paola Salvatore, J. Paul Kelleher, Ross J. Baldessarini
Citations249
SJR quartileQ1
SJR score5.27
SNIP3.68
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Short-term treatment with multiple antipsychotics was associated with major increases in drug exposure, adverse events, and time in the hospital but with no apparent gain in clinical benefit, requiring further testing in controlled prospective studies.
Abstract
Short-term treatment with multiple antipsychotics was associated with major increases in drug exposure, adverse events, and time in the hospital but with no apparent gain in clinical benefit. These findings require further testing in controlled prospective studies.
Keywords
Medicine
Schizophrenia BulletinThe Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
21,398 Citations1987Stanley R. Kay, Abraham Fiszbein +1 more
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
American Journal of PsychiatryThe McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence
465 Citations2003Mauricio Tohen, Carlos A. Zarate +6 more
Within 2-4 years of first lifetime hospitalization for mania, all but 2% of patients experienced syndromal recovery, but 28% remained symptomatic, only 43% achieved functional recovery, and 57% switched or had new illness episodes.
CNS DrugsEffects of Newer Antipsychotics on Extrapyramidal Function
315 Citations2002Daniel Tarsy, Ross J. Baldessarini +1 more
No atypical antipsychotic is clearly effective for motor abnormalities in Huntington’s disease or Tourette's syndrome, and the effect of these drugs on other neurological disorders have been well evaluated in only small numbers of patients.
The Journal of Clinical PsychiatryThe Increasing Use of Polypharmacotherapy for Refractory Mood Disorders
313 Citations2000Mark A. Frye, Terence A. Ketter +5 more
Increasing numbers of medications in more recent NIMH cohorts were required to achieve the same degree of improvement at hospital discharge, suggesting more systematic approaches to the complex regimens required for treatment of patients with refractory mood disorder are clearly needed.
The British Journal of PsychiatryMortality in schizophrenia
268 Citations1998J.L. Waddington, Hanafy A. Youssef +1 more
Receiving more than one antipsychotic concurrently was associated with reduced survival, in the face of little or no systematic evidence to justify the widespread use of antipsychotics, and over-cautious attitudes to the use of adjunctive anticholinergics may require re-evaluation.
The British Journal of PsychiatrySulpiride augmentation in people with schizophrenia partially responsive to clozapine
262 Citations1997Roni Shiloh, Z. Zemishlany +7 more
A subgroup of patients with chronic schizophrenia may substantially benefit from sulpiride addition to clozapine, and exhibited substantially greater and significant improvements in positive and negative psychotic symptoms.
Schizophrenia BulletinRecent Trends in Antipsychotic Combination Therapy of Schizophrenia and Schizoaffective Disorder: Implications for State Mental Health Policy
191 Citations2002Robin E. Clark, Stephen J. Bartels +2 more
The proportion of individuals with schizophrenia and schizoaffective disorder treated with atypical antipsychotics grew from 43 percent in 1995 to 70 percent in 1999, and the increase in multiple agent therapy appears to be broad-based.
PubMedRisperidone as an adjunct to clozapine therapy in chronic schizophrenics.
141 Citations1996David C. Henderson, Don Goff
In an open 4-week trial involving 12 treatment-resistant schizophrenic patients, the addition of risperidone to clozapine was well tolerated and produced significant reduction of symptoms, suggesting that this may be a useful clinical approach.
PubMedMovement disorders associated with atypical antipsychotic drugs.
131 Citations2002Stanley N. Caroff, Stephan C. Mann +2 more
Data from clinical trials reviewed in this article fulfill predictions based on preclinical findings that atypical antipsychotic drugs are associated with a reduced potential for inducing extrapyramidal symptoms (EPS) and other movement disorders.
The Canadian Journal of PsychiatryAntipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution
126 Citations2001Ric M. Procyshyn, Nathan B. Kennedy +2 more
Although antipsychotic polypharmacy persists today, as it has over the past 30 years, evidence-based data to support this controversial treatment strategy is lacking and clinicians are relying on their clinical experience, and perhaps intuition, to design antipsychotics polyphARMacy treatment protocols.
Medical CareUse of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
107 Citations2001Douglas Leslie, Robert A. Rosenheck
In the nation’s largest mental health system, a relatively small number of patients were prescribed multiple antipsychotic medications, but more than a third were dosed outside of the PORT recommended range.
American Journal of PsychiatryInpatient Antipsychotic Drug Use in 1998, 1993, and 1989
106 Citations2002Franca Centorrino, Marion Eakin +6 more
The dose of antipsychotics was greater for patients with psychotic illnesses than for those with affective illnesses, and higher doses were associated with greater clinical improvement, polypharmacotherapy, and younger patient age.
PubMedSelecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.
106 Citations1999Stephen M. Stahl
TheAtypical properties of first-line atypical antipsychotics as well as clozapine are reviewed here, with clinical pearls and dosing tips for each based upon a consensus of information from both clinical trials and clinical practice.
PubMedPharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
94 Citations1999Larry Ereshefsky
The pharmacologic properties of loxapine within its usable dosage range are quite complex and are the net sum of the parent's plus metabolites' contributions (demethylation and hydroxylation by cytochrome P450 enzymes).
Journal of Clinical PsychopharmacologyThe Safety and Pharmacokinetics of Quetiapine When Coadministered With Haloperidol, Risperidone, or Thioridazine
70 Citations2002Steven G. Potkin, Per T. Thyrum +4 more
Clinical stability can be maintained with good tolerability during the transition from quetiapine monotherapy to periods of coadministration with haloperidol, risperidone, or thioridazine.
PharmacopsychiatryRisperidone Augmentation of Clozapine
67 Citations1995Robyn McCarthy, Ken Terkelsen
Risperidone may be reasonably construed to be a medication with efficacy somewhere between clozapine and classical neuroleptics, and it may be especially well suited for use with clozAPine as a part of an augmentation strategy.
Schizophrenia ResearchAn open trial of risperidone augmentation of partial response to clozapine
66 Citations2001Christine G Taylor, Sean W. Flynn +4 more
Annals of Clinical PsychiatryOlanzapine augmentation of clozapine.
62 Citations1998Sanjay Gupta, Steven J. Sonnenberg +1 more
Olanzapine in combination with clozapine was found to be helpful in these patients, however, controlled studies are needed.
Annals of Clinical PsychiatryAdjunctive Loxapine in a Clozapine-Resistant Cohort of Schizophrenic Patients
61 Citations1996Samuel Mowerman, Samuel G. Siris
It is concluded that adjunctive treatment with typical neuroleptics for patients with an incomplete response to clozapine merits further investigation.
Clinical NeuropharmacologyCombined use of Risperidone and Olanzapine in the Treatment of Patients with Resistant Schizophrenia[colon] A Preliminary Case Series Report
50 Citations2000Vladimir Lerner, Bella Chudakova +2 more
The results suggest that this combination of risperidone-olanzapine combination may be useful, but the efficacy of this drug combination should be confirmed in larger study populations before its clinical application is considered.